Thermo Fisher Scientific Inc. Q3 2024 Earnings Summary

Thermo Fisher Scientific Inc. (NYSE:TMO), a leader in serving science, reported robust financial performance in its 2024 third-quarter earnings call on [date]. The company announced a revenue of $10.6 billion and an adjusted operating income of $2.36 billion, leading to an adjusted earnings per share (EPS) of $5.28.

Thermo Fisher raised its full-year adjusted EPS guidance to $21.35 to $22.07 and maintained its revenue forecast within $42.4 billion to $43.3 billion. Despite headwinds from reduced COVID-19 testing revenue, the company has shown resilience and strategic growth through innovation and acquisitions, such as the recent purchase of Olink.

Key Takeaways

• Thermo Fisher reported Q3 revenue of $10.6 billion and adjusted EPS of $5.28.
• Full-year adjusted EPS guidance raised to $21.35 to $22.07.
• Revenue guidance for the year remains at $42.4 billion to $43.3 billion.
• Innovations include the Iliad scanning transmission electron microscope and the MagMAX Sequential DNA/RNA kit.
• Partnership with the National Cancer Institute and the acquisition of Olink highlight strategic growth.
• The company anticipates strong financial performance to continue into 2024.

Company Outlook

• Thermo Fisher expects to maintain strong financial performance into 2024.
• Free cash flow reached $4.5 billion year-to-date.
• Adjusted EPS guidance for 2024 was raised following a strong Q3 performance.

Bearish Highlights

• Low-single-digit declines noted in the pharma and biotech sectors.
• Flat growth in diagnostics and healthcare due to reduced COVID-19 testing revenue.

Bullish Highlights

• Strong momentum in bioproduction with sequential and year-over-year growth.
• Clinical sequencing business performing well with advancements in companion diagnostics.

Misses

• Core organic growth was flat for the quarter, slightly missing expectations.
• Pandemic-related pressures and muted economic activity in China may impact future performance.

Q&A Highlights

• CEO Marc Casper expressed optimism for Q4, expecting a return to organic growth.
• Operating margins are expected to increase in Q4 due to revenue growth and seasonal factors.
• Analytical instruments segment achieved 3% organic growth, despite muted demand for routine capital equipment.

Thermo Fisher's earnings call showcased a company navigating the post-pandemic market with strategic innovations and partnerships. The extension of the Optilite Freelight MX Kappa Kit in the EU and the integration of Olink demonstrate Thermo Fisher's commitment to expanding its product offerings and market position. With a steady financial outlook, Thermo Fisher Scientific is positioned to continue delivering value to stakeholders while overcoming global market challenges.

InvestingPro Insights

Thermo Fisher's financial performance and growth initiatives are supported by key metrics from InvestingPro. The company's market capitalization stands at $218.51 billion. Despite a slight revenue decline of 2.71% over the last twelve months, profitability remains strong, with a gross profit margin of 40.69% and an operating income margin of 17.58%.

Thermo Fisher has raised its dividend for 6 consecutive years, reflecting a commitment to shareholder returns.

Full Transcript – Thermo Fisher Scientific (TMO) Q3 2024

Operator: Good morning, ladies and gentlemen and welcome to the Thermo Fisher Scientific 2024 Third Quarter Conference Call. My name is Ezra and I will be your coordinator today. [Operator Instructions].

Rafael Tejada: Good morning, and thank you for joining us. On the call with me today is Marc Casper, our Chairman, President, and Chief Executive Officer and Stephen Williamson, Senior Vice President and Chief Financial Officer. …

• Full earnings call transcript available.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.